Any current/future capex/capital investment/strategic investment?

Archean Chemical Industries is executing a capex for bromine derivative projects in two phases: Phase 1 includes brominated clear brine fluids, PTA synthesis catalysts, and allied products; Phase 2 focuses on flame retardants. The flame retardant plant commissioning is targeted for Q1 FY25, with possible early commissioning in FY24, but it's subject to technical product evaluations and customer approvals. The bromine capacity is being expanded by 32,000 tons, and bromine derivatives capacity by 28,000 tons, with full utilization expected around FY26. R&D setup is operational with a curre

Future growth expectations in sales/revenue/volumes?

Bromine sales volume is expected to increase from current ~4,273 tons in Q1 FY24 to around 25,000 to 28,000 tons by FY26 with ~90% capacity utilization. Bromine derivatives capacity of 28,000 tons expected to have ~24,000-25,000 tons volume by FY26. Bromine consumed in derivatives expected to be 13,000-16,000 tons. Salt segment maintains strong volume run rate of about 1 million tons per quarter; demand robust due to chlorine usage expansion. SOP (Sulfate of Potash) volumes expected to grow with domestic market traction and stabilization anticipated in current financial year. Downstrea

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects steady business in coming quarters as export demand for bromine picks up after destocking phase. Bromine derivative capacity utilization anticipated to reach 90% by FY’26, supporting higher volumes. Flame retardant plant commissioning expected in Q1 FY’25, with full utilization targeted by FY’26. EBITDA margins have held strong at around 41% in Q1 FY24, with efforts on cost rationalization (power, transportation) yielding savings; margin improvement possible with ramp-up. Net profit after tax in Q1 FY24 grew 11% YoY, indicating earnings growth despite revenue moderation. Domest

Archean ChemicalQ1 FY24Chemicals & Petrochemicals

Archean Chemical Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹475P/E: 61.5Market Cap: ₹6.0K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Bromine sales volume is expected to increase from current ~4,273 tons in Q1 FY24 to around 25,000 to 28,000 tons by FY26 with ~90% capacity utilization.
Bromine derivatives capacity of 28,000 tons expected to have ~24,000-25,000 tons volume by FY26. Bromine consumed in derivatives expected to be 13,000-16,000 tons.
Salt segment maintains strong volume run rate of about 1 million tons per quarter; demand robust due to chlorine usage expansion.
SOP (Sulfate of Potash) volumes expected to grow with domestic market traction and stabilization anticipated in current financial year.
Downstream bromine derivative projects (Phase 1 and 2 including flame retardants) expected full utilization by FY25/FY26, with flame retardants commissioning targeted in Q1 FY25.
Export market demand for bromine picking up with recovering global customers; domestic demand remains firm despite price pressures.
Overall revenue growth supported by bromine, derivatives, salt, and SOP segments as capacity expansion and market recovery progresses.

Margin guidance

Category 3

Company expects steady business in coming quarters as export demand for bromine picks up after destocking phase.
Bromine derivative capacity utilization anticipated to reach 90% by FY’26, supporting higher volumes.
Flame retardant plant commissioning expected in Q1 FY’25, with full utilization targeted by FY’26.
EBITDA margins have held strong at around 41% in Q1 FY24, with efforts on cost rationalization (power, transportation) yielding savings; margin improvement possible with ramp-up.
Net profit after tax in Q1 FY24 grew 11% YoY, indicating earnings growth despite revenue moderation.
Domestic market demand remains firm, aiding stable revenue streams despite pricing pressure.
Sulfate of Potash (SOP) volumes expected to stabilize within FY24, contributing to future growth.
Expansion in bromine and bromine derivatives capacities underpin medium-term volume and profit growth prospects.

See what Archean Chemical management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript from the earnings call (Pages 1-15) does not mention any current or planned fundraising activities through debt or equity. Key points regarding capital expenditures and capacity expansions are: - The company is undertaking capital expenditure for bromine and bromine derivatives capacity expansions. - Capex is being deployed simultaneously for downstream projects, including brominated clear brine fluids, PTA synthesis catalysts, and flame retardants. - No specific mention of raising funds via debt or equity was made during the call. - Focus is on organic growth funded likely through internal accruals or existing resources. Therefore, based on the available information, there are no indications of imminent debt or equity fundraising plans.

Order book

The transcript from the earnings call of Archean Chemical Industries Limited does not explicitly mention the current or expected order book or pending orders in clear terms. However, some related points can be summarized: - Export demand is picking up gradually, with some customers coming back to contract volumes after a period of inventory liquidation. - Domestic demand for bromine remains firm despite pricing pressure. - The company anticipates steady business in the coming quarters with increasing marketing efforts. - Flame retardant derivative capacity commissioning expected in Q1 FY25, with marketing and approvals ongoing. - Clear brine fluid and PTA synthesis catalysts being aggressively marketed post-Diwali with a target of 70% utilization in the first year. - The company foresees a solid strength as a fully integrated player with bromine derivative expansion. - No explicit numeric data on current orderbook or pending orders provided in the available pages.

See what Archean Chemical management said on order book — free account, 30 seconds.

Capex plans

Yes

Archean Chemical Industries is executing a capex for bromine derivative projects in two phases: Phase 1 includes brominated clear brine fluids, PTA synthesis catalysts, and allied products; Phase 2 focuses on flame retardants.
The flame retardant plant commissioning is targeted for Q1 FY25, with possible early commissioning in FY24, but it's subject to technical product evaluations and customer approvals.
The bromine capacity is being expanded by 32,000 tons, and bromine derivatives capacity by 28,000 tons, with full utilization expected around FY26.
R&D setup is operational with a current 4-member team, planned to grow to 10 members by FY25 focusing on industry applications and product trials.
Industrial salt washeries expansion with two additional conveyor lines is targeted for commissioning around March 2024, pending weather conditions.
Overall, capex and strategic investments are aimed at strengthening integration and product portfolio to enhance competitiveness and market share.

Track Archean Chemical — get its next earnings analysis in your feed

How does Archean Chemical rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisArchean Chemical

Rev 3Mar 3

See where Archean Chemical sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Archean Chemical rank in Chemicals & Petrochemicals?

Compare Archean Chemical against every Chemicals & Petrochemicals company (Q1 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Archean Chemical's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Archean Chemical Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Archean Chemical rank in Chemicals & Petrochemicals?

Continue your research

What Archean Chemical's management said in earlier quarters

Others in Chemicals & Petrochemicals this season